Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
Phase III In-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon Phase III In-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo ...
Raynaud's Disease;Scleroderma;Autoimmune Diseases
Drug: Topical AmphiMatrix with nitroglycerin (MQX-503)